Clinical Trials · NCT04269642
SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- Peptron, Inc.
- Enrollment
- 99
- Start date
- Mar 2020
- Locations
- 5 sites, South Korea
- Primary endpoint
- Change of MDS-UPDRS part 3 score